Lupus Erythematosus, Systemic: Clinical Trials

1,406 trials for Lupus Erythematosus, Systemic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

540 completed, 272 recruiting, 225 unknown, 110 terminated. 331 Phase 2, 315 Phase 1, 232 Not applicable, 156 Phase 3, 79 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2331Completed 149, Recruiting 58, Terminated 41, Unknown 32, Active not recruiting 20, Not yet recruiting 17, Withdrawn 12, Enrolling by invitation 2
Phase 1315Completed 108, Recruiting 99, Not yet recruiting 29, Terminated 22, Active not recruiting 17, Unknown 17, Withdrawn 17, Enrolling by invitation 5, Suspended 1
Not applicable232Completed 107, Unknown 45, Recruiting 27, Not yet recruiting 18, Active not recruiting 16, Terminated 11, Withdrawn 4, Enrolling by invitation 3, Suspended 1
Phase 3156Completed 54, Terminated 32, Unknown 19, Active not recruiting 17, Recruiting 17, Withdrawn 10, Not yet recruiting 4, Enrolling by invitation 3
Phase 479Completed 33, Unknown 16, Recruiting 14, Withdrawn 7, Active not recruiting 4, Terminated 4, Not yet recruiting 1
Early Phase 151Recruiting 21, Not yet recruiting 8, Unknown 8, Completed 5, Terminated 4, Withdrawn 3, Active not recruiting 1, Suspended 1

Follow Lupus Erythematosus, Systemic: new trials by email Literature Review of Lupus Erythematosus, Systemic trials Research Report on Lupus Erythematosus, Systemic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
CB-010 - Systemic Lupus Erythematosus, Lupus
Phase 1WithdrawnCaribou Biosciences, Inc.2027-12-012025-09-19
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
TEAM-LEADS - Lupus, Dermatomyositis, Juvenile
Not applicableNot yet recruitingDuke University252027-02-012026-05-27
The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.
belantamab mafodotin to the existing stable standard background therapy - SLE - Systemic Lupus Erythematosus
Phase 2Not yet recruitingMedical Association for the Study of Cancer Biology and Treatment122027-02-012026-09-28
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus
Phase 1Not yet recruitingShenzhen MagicRNA Biotechnology Co., Ltd122026-12-312026-08-12
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 3Not yet recruitingBristol-Myers Squibb23002026-12-312026-09-03
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Phase 1Not yet recruitingGustave Roussy, Cancer Campus, Grand Paris62026-12-012026-09-02
MYTP01 for Immune-Mediated Diseases
MYTP01, MYTP01 Placebo - IgA Nephropathy, Kidney Transplant Recipients
Not applicableNot yet recruitingZhejiang Provincial People's Hospital1602026-12-012026-11-04
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
DKB903 - Rheumatoid Arthritis and Systemic Lupus Erythematosus
Phase 1Not yet recruitingNovartis Pharmaceuticals902026-12-012026-11-06
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
QLS2416 Injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
Phase 1Not yet recruitingShanghai Qilu Pharmaceutical Research and Development Center LTD762026-12-012026-10-30
Dual-targeting of B & T Cell Pathways Evaluation Trial
DFI205 bispecific antibody - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Phase 1 / Phase 2RecruitingDiabetes Free, Inc.722026-12-012026-11-18
Deciphering the Genetic Architecture of Autoimmune Diseases
Autoimmune Diseases
RecruitingNational Human Genome Research Institute (NHGRI)3002026-11-232026-11-18
A Study of IPG11406 Tablets in Participants With Lupus Nephritis
IPG11406 tablet, placebo - Lupus Nephritis
Phase 2Not yet recruitingNanjing Immunophage Biotech Co., Ltd1922026-11-202026-11-16
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis
Phase 1 / Phase 2Not yet recruitingPfizer542026-11-192026-10-01
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Dapirolizumab pegol (DZP) - Systemic Lupus Erythematosus
Phase 1Not yet recruitingUCB Biopharma SRL252026-11-152026-11-18
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Bedside quantitative sensory testing - Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2252026-11-092026-11-12
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Cevostamab, Tocilizumab - Lupus Erythematosus, Systemic
Phase 1RecruitingGenentech, Inc.462026-11-022026-11-05
Cardiac Imaging in Systemic Disorders: the ORACLES Registry
data collection - Lupus
Not yet recruitingAssistance Publique - Hôpitaux de Paris15002026-11-012026-02-13
Effectiveness of Resonance Frequency Breathing Exercises in Patients With Systemic Lupus Erythematosus and Central Sensitization
Resonance Frequency Breathing, Standard Exercise Program - Systemic Lupus Erythematosus (SLE), Central Sensitization
Not applicableNot yet recruitingIstanbul University - Cerrahpasa382026-11-012026-10-13
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
Depletion of CD3/CD19 in an autologous stem cell transplant - Systemic Lupus Erythematosus, Systemic Sclerosis
Phase 2RecruitingStephan Grupp MD PhD202026-11-012026-11-16
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease
Phase 1Not yet recruitingBristol-Myers Squibb602026-10-302026-10-14

Showing 20 of 1406. Sign in to see all of them.

Narrower conditions

Lupus Nephritis (337)  ·  Autoimmune Diseases (133)  ·  Arthritis, Rheumatoid (121)  ·  Scleroderma, Systemic (105)  ·  Sjogren's Syndrome (69)  ·  Myositis (66)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (45)  ·  Arthritis (36)  ·  Connective Tissue Diseases (36)  ·  Immune System Diseases (35)  ·  Dermatomyositis (32)  ·  Antiphospholipid Syndrome (28)  ·  Scleroderma, Diffuse (27)  ·  Motor Activity (26)

Broader conditions

Skin and Connective Tissue Diseases (1403)  ·  Immune System Diseases (1371)  ·  Connective Tissue Diseases (1370)  ·  Autoimmune Diseases (1273)  ·  Urogenital Diseases (364)  ·  Female Urogenital Diseases and Pregnancy Complications (359)  ·  Female Urogenital Diseases (356)  ·  Male Urogenital Diseases (356)  ·  Urologic Diseases (355)  ·  Kidney Diseases (343)  ·  Glomerulonephritis (327)  ·  Nephritis (324)  ·  Musculoskeletal Diseases (240)  ·  Skin Diseases (197)

Interventions

Cyclophosphamide (61)  ·  Mycophenolic Acid (60)  ·  belimumab (51)  ·  Prednisone (30)  ·  Rituximab (29)  ·  Blood Specimen Collection (28)  ·  Standard of Care (26)  ·  anifrolumab (25)  ·  fludarabine (25)  ·  Azathioprine (21)  ·  Methylprednisolone (19)  ·  Tacrolimus (19)  ·  Adrenal Cortex Hormones (18)  ·  epratuzumab (13)  ·  telitacicept (13)

Sponsors

Assiut University (52)  ·  AstraZeneca (35)  ·  GlaxoSmithKline (31)  ·  Assistance Publique - Hôpitaux de Paris (22)  ·  Amgen (20)  ·  Novartis Pharmaceuticals (19)  ·  Bristol-Myers Squibb (18)  ·  Sohag University (17)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (16)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (16)  ·  Duke University (14)  ·  RenJi Hospital (14)  ·  UCB Pharma (14)  ·  NYU Langone Health (13)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (13)

Countries

United States (533)  ·  China (334)  ·  France (178)  ·  Spain (162)  ·  Germany (136)  ·  Mexico (122)  ·  Poland (122)  ·  Brazil (106)  ·  Argentina (105)  ·  Taiwan (103)  ·  United Kingdom (102)  ·  Canada (97)  ·  South Korea (96)  ·  Italy (91)  ·  Japan (82)

Top investigators

Sarfaraz A Hasni, M.D. (8)  ·  Qiubai Li, Professor (6)

Results publications

PMID 33687069, PMID 37528520, PMID 34628605, PMID 34741731, PMID 34531304, PMID 38775637, PMID 39115551, PMID 39208825, PMID 38216728, PMID 38724182, PMID 40465397, PMID 23213069, PMID 25777546, PMID 31302695, PMID 31660791, PMID 33568389, PMID 33693991, PMID 37228028, PMID 39586304, PMID 18634158, PMID 22087680, PMID 22275291, PMID 22337213, PMID 22553077, PMID 22674457, PMID 23524886, PMID 23681782, PMID 23754628, PMID 24187095, PMID 24254965, PMID 25396065, PMID 25988278, PMID 26138472, PMID 26290435, PMID 26867033, PMID 27099766, PMID 27220348, PMID 27598855, PMID 27723281, PMID 28925994, PMID 29045736, PMID 29381843, PMID 29409143, PMID 29445400, PMID 29450636, PMID 29699792, PMID 31537547, PMID 31790472, PMID 32918459, PMID 33830377

NIH funding

2023 (28), 2025 (13), 2017 (11), 2019 (9), 2015 (7), 2018 (7), 2014 (6), 2016 (5), 2008 (3), 2009 (2), P30AG064199 (2), U01AR042540 (2), K01AR060026 (1), K08CA237619 (1), K23AR078177 (1)